Clearmind Medicine reports positive safety data from CMND-100 trial

Clearmind Medicine Inc. (NASDAQ: CMND) reported additional positive safety results from the second cohort of its Phase I/IIa clinical trial evaluating CMND-100 for alcohol use disorder treatment. The company said the results from six patients reinforce the drug candidate's safety and tolerability profile.

The trial data showed no serious adverse events and overall good tolerability, consistent with results from the first cohort. The company's Data and Safety Monitoring Board previously provided unanimous approval to advance to the second cohort.

The multinational, multicenter study evaluates the safety, tolerability, pharmacokinetics, and preliminary efficacy of CMND-100 in patients with moderate to severe alcohol use disorder. The second cohort was conducted at Johns Hopkins University, Tel Aviv Sourasky Medical Center, and Hadassah Medical Center.

CMND-100 is described as a proprietary non-hallucinogenic MEAI-based oral drug candidate. The company completed treatment of the second cohort following clearance from the Data and Safety Monitoring Board.

"These additional topline safety results from the second cohort further validate and reinforce the positive profile we observed in the first cohort," said Dr. Adi Zuloff-Shani, Chief Executive Officer of Clearmind Medicine.

Clearmind Medicine is a clinical-stage biotech company focused on developing psychedelic-derived therapeutics. The company holds 19 patent families, including 31 granted patents. Shares trade on NASDAQ under the symbol CMND and the Frankfurt Stock Exchange under CWY0.

You May Also Be Interested In